Therapeutic Response Testing
Therapeutic Response Testing - Related Videos
10:45
Clinically Relevant Transplantable Tumor Models for Studying Metastatic Ovarian Cancer and Therapeutic Response in Mouse
0 Views •
2026
Here we present a step-by-step protocol for establishing the intraperitoneal and the intrabursal tumor models to study ovarian cancer cancer progression, metasatsis, and therapeutic response. Further, we describe how to use luciferase-based non-invasive in vivo imaging in these models to monitor tumor progression in mouse.
07:47
Anxiety Testing
0 Views •
2023
Anxiety is a commonly observed behavioral disorder that stems from fear. It is described as increased restlessness, or unpleasant feelings of fear over anticipated events. Experimenters often use rodent models to better understand anxiety disorders in humans. They use different paradigms, like exposing rodents to bright spaces or loud sounds, which are known to induce fear. These tests combined with other interventions such as surgery or drug-administration may assist researchers in pinpointing...
09:24
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
0 Views •
Cited by 20 •
2016
Patient-derived xenografts of glioblastoma multiforme can be miniaturized into living microtumors using 3D human biogel culture system. This in vivo-like 3D tumor assay is suitable for drug response testing and molecular profiling, including kinomic analysis.
12:09
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
0 Views •
Cited by 14 •
2013
We describe a novel in vivo imaging technique that couples fluorescent chimeric mice with intracranial windows and high-resolution 2-photon microscopy. This imaging platform aids studies of dynamic changes in brain tissue and microvasculature, at a single-cell level, following pathological insults and is adaptable to assess intracranial drug delivery and distribution.
07:10
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
0 Views •
Cited by 17 •
2011
A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described. The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.
FAQs
A baseline provides the reference needed to judge change after treatment begins. Repeating assessments at defined time points helps distinguish a treatment-related response from the patient’s prior condition or natural disease progression. This structured comparison also shows whether improvement, lack of benefit, or worsening persists over time rather than relying on a single observation.
Dose is interpreted alongside the findings observed after treatment. A response at one dose may differ from the response at another, making dose-linked assessment useful when clinicians consider adjustment. Comparing treatment exposure with clinical measurements, biomarkers, imaging, or functional findings can help identify whether a regimen is producing benefit, insufficient effect, or harmful effects.
Therapeutic response testing can combine clinical measurements, laboratory biomarkers, imaging, and functional assessments. These sources provide different views of treatment-related change, so using the appropriate measure depends on what aspect of the patient, disease, or biological system is being evaluated. Comparing results with baseline findings strengthens interpretation and supports a more complete assessment of outcome.
The pattern and direction of findings help separate useful treatment effects from adverse outcomes. Evidence of limited or absent benefit may indicate ineffective therapy or emerging resistance, while harmful clinical or biological changes may suggest toxicity. Repeated assessments are important because they can identify these concerns early and support decisions about treatment selection, monitoring, or dose adjustment.
A typical workflow begins by recording relevant baseline findings, administering or continuing the treatment, and evaluating the patient or biological system at defined follow-up points. Investigators then compare post-treatment results with baseline data, consider the treatment dose and timing, and classify the observed pattern as beneficial, ineffective, or harmful. The findings inform subsequent clinical or research decisions.
It is useful when clinicians need evidence that a selected intervention is producing the intended outcome or when the current dose may require reconsideration. Response data can show whether treatment should be continued, adjusted, or evaluated for possible resistance or toxicity. This supports decisions based on observed patient findings rather than treatment exposure alone.
In clinical trials, therapeutic response measurements serve as outcome measures for comparing treatment effects across defined assessments. Clinical findings, laboratory biomarkers, imaging, or functional results can document changes associated with an intervention. Standardized baseline and follow-up comparisons help investigators evaluate effectiveness and harmful effects, making response data central to judging a treatment’s performance.
Response assessment contributes to precision medicine by linking an individual’s treatment outcome with biological and clinical characteristics. When these characteristics are considered alongside measured changes after treatment, researchers and clinicians can examine why responses differ between individuals. This relationship can support more individualized treatment selection, monitoring, and dose decisions while preserving direct attention to observed outcomes.